These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12456059)

  • 1. Measuring cognition in advanced Alzheimer's disease for clinical trials.
    Schmitt FA; Cragar D; Ashford JW; Reisberg B; Ferris S; Möbius HJ; Stöffler A
    J Neural Transm Suppl; 2002; (62):135-48. PubMed ID: 12456059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil.
    Levine SZ; Yoshida K; Goldberg Y; Samara M; Cipriani A; Efthimiou O; Iwatsubo T; Leucht S; Furukawa TA
    Evid Based Ment Health; 2021 May; 24(2):56-61. PubMed ID: 33023920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target symptoms and outcome measures: cognition.
    Kirk A
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S42-6. PubMed ID: 17469681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    Schmitt FA; Ashford W; Ernesto C; Saxton J; Schneider LS; Clark CM; Ferris SH; Mackell JA; Schafer K; Thal LJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S51-6. PubMed ID: 9236953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients.
    Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
    Alzheimers Dement; 2009 Sep; 5(5):375-9. PubMed ID: 19751916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
    Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J
    J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
    Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
    J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
    Balsis S; Benge JF; Lowe DA; Geraci L; Doody RS
    Clin Neuropsychol; 2015; 29(7):1002-9. PubMed ID: 26617181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
    Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
    Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
    Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil for mild and moderate Alzheimer's disease.
    Birks J S; Melzer D
    Cochrane Database Syst Rev; 2000; (2):CD001190. PubMed ID: 10796620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.